Systemic biases in medical research
Systemic biases in medical research are structural distortions in the production, publication, and regulatory review of medical science that critics allege serve the financial interests of the pharmaceutical industry rather than the public health — including publication bias, industry funding bias, the replication crisis, pharmaceutical ghostwriting, and the institutional legacy of the Flexner Report. These biases are cited in suppressed technology and alternative medicine research as the mechanisms by which institutional medicine maintains its monopoly on acceptable treatments while excluding efficacious alternatives.
Publication bias
Publication bias is the systematic tendency for studies with positive results to be published while studies with negative or null results remain unpublished — creating a distorted evidence base in which treatments appear more effective than they are. The Infectious Disease Society of America dismissed the evidence for ivermectin efficacy against COVID-19 specifically because "almost all of the published trials are positive" — interpreting uniformly positive results as evidence of publication bias rather than drug efficacy.
The standard tool for detecting publication bias — pre-registration of clinical trials — showed no evidence of publication bias in the ivermectin literature, yet the IDSA maintained its negative recommendation regardless: "their objection wasn't a real objection. It was stalling." This pattern — demanding ever-higher standards of evidence while ignoring observational data from countries where the drug was deployed — suggested that "what is driving here has to do with profits."
Replication crisis
The replication crisis refers to the finding, first systematically documented by John Ioannidis in his 2005 paper "Why Most Published Research Findings Are False," that the majority of published scientific studies cannot be replicated by independent researchers. Critics have estimated that as many as 90% of new medical studies contain fraudulent or irreproducible findings, with only approximately one-third of the remainder reproducible by other scientists.
The replication crisis is particularly acute in pharmacological research, where industry-funded studies are significantly more likely to produce positive results than independently funded studies examining the same drug — a pattern consistent with systemic industry influence over research outcomes rather than genuine scientific disagreement.
The Flexner Report legacy
Main article:
Flexner Report
The Flexner Report of 1910 — funded by the Carnegie Foundation for the Advancement of Teaching with involvement from Rockefeller interests — resulted in the closure of over half of all American medical schools, particularly those teaching homeopathy, naturopathy, and other non-pharmaceutical approaches. Critics allege the report was designed not to improve medical education but to establish a pharmaceutical monopoly by eliminating competing modalities. The post-Flexner system has been described as "a hostile takeover of natural and holistic medicine by a small group of ultra wealthy industrialists."
The Flexner restructuring specifically eliminated electrotherapy research that had been active since the 1890s — including work presented by Nikola Tesla himself at annual meetings of the American Electro Therapeutic Association — because electromagnetic treatments "could not generate recurring monthly revenue in the way that pharmaceutical prescriptions could."
Industry funding bias
The pharmaceutical industry's role as the primary funder of clinical research creates structural conflicts of interest throughout the research pipeline. Industry-funded studies are conducted, analyzed, and published under conditions that systematically favor positive results for the sponsor's product. Mechanisms include selective outcome reporting, data dredging, study design choices that favor the test drug, and the use of active placebos that produce side effects (allowing researchers to unblind the study by observing which patients experience side effects).
The insistence on randomized controlled trials as the sole acceptable form of evidence — described as "mania" — is itself a bias-producing mechanism, since only pharmaceutical companies have the resources to fund large-scale RCTs, effectively ensuring that only patentable, profitable drugs can generate the evidence required for regulatory approval.
Pharmaceutical ghostwriting
Ghostwriting in medical research refers to the practice in which pharmaceutical companies draft scientific papers presenting their products favorably, then recruit academic physicians to attach their names as authors — lending institutional credibility to what are effectively corporate marketing documents. The practice has been documented in litigation against GlaxoSmithKline, Merck, Pfizer, and other major pharmaceutical firms.
Economic incentives in drug-development prioritization
The process of developing and testing a new drug and obtaining regulatory approval is very expensive, and manufacturers naturally prioritise researching drugs expected to yield a large return on investment over less profitable ones. This structural dynamic means that promising drugs lacking strong profit potential are often not researched. Although governments and charitable groups sometimes fund research into such drugs, the amount of non-industry funding is small relative to manufacturer-funded research, which dominates drug-development spending.
In what researchers have described as a case of perverse incentives, this funding pattern means that drugs which merely keep a disease in check or alleviate symptoms tend to be prioritised over drugs that can actually cure a disease — since the former must be taken long-term, generating more doses sold — and drugs that cost the patient a lot of money are prioritised over cheaper alternatives.
A key determinant of whether a drug is considered profitable, and therefore worth researching, is whether it can be patented. A patented compound can be sold only by the patent holder, who can therefore charge high prices; an unpatented compound cannot be sold much above manufacturing cost because other manufacturers will undercut any markup.
Many areas widely considered to have strong potential for patient benefit receive comparatively little research investment for these reasons:
- New antibiotics (typically require only a short course of treatment)
- Vaccines (typically require only a single dose, or a dose every year or every few years)
- New uses for existing drugs whose patents have expired
- Herbal remedies (unpatentable in themselves, although identifying an active compound in a plant, synthesising a slightly modified variant that can be patented, and developing that variant as a new drug is a common drug-development strategy)
- Non-medical interventions (for example, the effects of exercise or obesity on a particular condition)
- Medical devices (reusable, so only the most expensive devices generate revenue comparable to a drug that must be bought each time)
Many of these are widely recognised as promising research areas even by mainstream scientists, yet attract relatively little sustained investment.
Connection to technology suppression
The systemic biases in medical research operate as the scientific-institutional complement to the Flexner Report's educational restructuring and the FDA's regulatory enforcement: together they form a system in which alternative treatments — including Rife frequency therapy, Reich's orgone therapy, and electrotherapy — cannot generate the evidence required for approval because the evidence standards themselves are designed to exclude non-patentable therapies.